However, the underlying mechanism remains unclear, and this study inspired us to confirm whether HNMT expression in TNBC tumor tissue can be used as a molecular marker to identify patients who respond to anti-HER2 ACD (T-Dxd) therapy. This evidence concerns the gene ERBB2 and neoplasm.